Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 989,200 shares, a decline of 8.4% from the July 15th total of 1,080,000 shares. Currently, 2.8% of the company’s stock are sold short. Based on an average daily volume of 131,000 shares, the short-interest ratio is presently 7.6 days.

Insider Buying and Selling at Athira Pharma

In other news, Director Kelly A. Romano purchased 27,400 shares of the stock in a transaction dated Monday, June 24th. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the acquisition, the director now owns 80,715 shares of the company’s stock, valued at $195,330.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Athira Pharma news, Director Kelly A. Romano acquired 15,000 shares of the stock in a transaction dated Friday, June 21st. The stock was purchased at an average price of $2.26 per share, with a total value of $33,900.00. Following the transaction, the director now directly owns 53,315 shares of the company’s stock, valued at $120,491.90. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kelly A. Romano bought 27,400 shares of Athira Pharma stock in a transaction that occurred on Monday, June 24th. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the transaction, the director now directly owns 80,715 shares in the company, valued at $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Athira Pharma

Hedge funds have recently added to or reduced their stakes in the business. Private Advisor Group LLC purchased a new position in shares of Athira Pharma during the 4th quarter valued at about $32,000. Rothschild Investment LLC purchased a new position in Athira Pharma during the second quarter valued at approximately $34,000. Mirador Capital Partners LP purchased a new position in Athira Pharma during the first quarter valued at approximately $57,000. XTX Topco Ltd acquired a new position in Athira Pharma in the second quarter valued at approximately $60,000. Finally, Invst LLC purchased a new stake in Athira Pharma in the 2nd quarter worth approximately $68,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $19.00 price objective on shares of Athira Pharma in a report on Thursday, June 20th. Rodman & Renshaw assumed coverage on shares of Athira Pharma in a report on Monday. They issued a “buy” rating and a $22.00 price target for the company.

Athira Pharma Stock Up 17.1 %

Shares of NASDAQ:ATHA opened at $3.43 on Tuesday. The business has a 50-day moving average price of $2.93 and a 200-day moving average price of $2.81. The stock has a market cap of $131.47 million, a price-to-earnings ratio of -1.12 and a beta of 2.90. Athira Pharma has a 52-week low of $1.33 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. As a group, equities analysts anticipate that Athira Pharma will post -2.79 EPS for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.